Patients with cancer (n=555) | |
---|---|
Age, years (IQR) | 62 (52–71) |
Male gender, n (%) | 197 (40%) |
BMI kg/m2, (IQR) | 25.0 (22.6–28.4) |
Comorbidities | |
Known CAD, n (%) | 28 (5%) |
Valvular disease, n (%) | 8 (1%) |
Heart failure, n (%) | 38 (7%) |
Stroke/TIA, n (%) | 17 (3%) |
PAD, n (%) | 19 (3%) |
Diabetes mellitus, n (%) | 43 (8%) |
Arterial hypertension, n (%) | 250 (45%) |
CKD, n (%) | 31 (6%) |
COPD, n (%) | 113 (20%) |
Currently smoking, n (%) | 118 (21%) |
Sinus rhythm, n (%) | 509 (96%) |
PM or ICD, n (%) | 6 (1%) |
Medication | |
Beta-blocker, n (%) | 123 (22%) |
ACE or ARB, n (%) | 166 (31%) |
Aldosterone antagonist, n (%) | 15 (3%) |
Digitalis, n (%) | 3 (1%) |
ASS, n (%) | 111 (20%) |
Planned therapy* | 383 (89%) |
Surgery, n (%) | 318 (75%) |
Anticancer chemotherapy, n (%) | 298 (70%) |
Hormone therapy, n (%) | 66 (16%) |
Radiation therapy, n (%) | 146 (34%) |
Antibody therapy, n (%) | 80 (19%) |
Bone marrow transplantation, n (%) | 4 (1%) |
Normal cardiac status, n (%) | 408 (75%) |
Serum creatinine, mg/dL (IQR) | 0.88 (0.77–1.03) |
GFR, mL/min/1.73 m2 (IQR) | 74.5 (63.7–86.0) |
hsTnT, ng/mL (IQR) | 0.006 (0.003–0.010) |
NT-proBNP, pg/mL (IQR) | 128 (64–279) |
MR-proANP, pmol/L (IQR) | 66.5 (47.2–107.3) |
MR-proADM, nmol/L (IQR) | 0.56 (0.44–0.72) |
CT-proET-1, pmol/L (IQR) | 52.5 (40.3–68.1) |
Copeptin, pmol/L (IQR) | 4.60 (2.90–8.28) |
CRP, mg/L (IQR) | 0 (0–1) |
IL-6, pg/mL (IQR) | 2 (2–3) |
Fibronectin, mg/dL (IQR) | 42 (35–48) |
Haptoglobin, mg/dL (IQR) | 137 (93–201) |
SAA, µg/mL (IQR) | 8 (4–26) |
Continuous variables are given as medians and IQR. Counts are given as numbers and percentages.
*Information about planned therapy was collected for all patients excluding those with myeloproliferative neoplasias.
ARB, angiotensin receptor blocker; ASS, acetyl salicylic acid; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; CT-proET-1, C-terminal pro endothelin-1; GFR, glomerular filtration rate; hsTnT, high-sensitive troponin T; ICD, implantable cardioverter defibrillator; IL-6, interleukin 6; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide; PAD, peripheral artery disease; PM, pacemaker; SAA, serum amyloid A; TIA, transitory ischaemic attack.